The Hippo pathway as a drug target in gastric cancer

Cancer Lett. 2018 Apr 28:420:14-25. doi: 10.1016/j.canlet.2018.01.062. Epub 2018 Jan 31.

Abstract

The Hippo tumor suppressor pathway is critical for balancing cellular differentiation and proliferation in response to cell-cell contact, mechanical signals and diffusible signals such as lysophosphatidic acid. Hippo pathway signaling is frequently dysregulated in gastric cancer (GC), as well as many other kinds of solid tumors, contributing to multiple aspects of malignant progression including unchecked cell division and metastasis. Considering the importance of this Hippo pathway in cancer, its pharmacological disruption may be of huge benefit in the fight against this disease. In this review, we summarize the components of the Hippo pathway, its crosstalk with other major oncogenic signaling pathways, common mechanisms of its dysregulation, as well as potential therapeutic approaches of targeting this pathway for cancer treatment, specifically in a GC context.

Keywords: Gastric cancer; Hippo pathway; YAP.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials as Topic
  • Gene Expression Regulation, Neoplastic / drug effects
  • Hippo Signaling Pathway
  • Humans
  • Protein Serine-Threonine Kinases / metabolism
  • Signal Transduction / drug effects*
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / metabolism

Substances

  • Antineoplastic Agents
  • Protein Serine-Threonine Kinases